A study in healthy men to test how itraconazole influences the amount of BI 764198 in the blood

2025-523135-19-00 Protocol 1434-0021 Human pharmacology (Phase I) - Other Ended

Start 6 Feb 2026 · End 10 Apr 2026 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 1434-0021

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 14
Countries 1
Sites 1

Healthy volunteer trial

Key facts

Sponsor
Boehringer Ingelheim International GmbH
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male
Therapeutic area
Not possible to specify
Trial duration
6 Feb 2026 → 10 Apr 2026
Decision date (initial)
2025-12-16
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2025-523135-19-00
WHO UTN
U1111-1325-2539

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Healthy volunteer trial

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Boehringer Ingelheim International GmbH

Sponsor organisation
Boehringer Ingelheim International GmbH
Address
Binger Strasse 173
City
Ingelheim Am Rhein
Postcode
55216
Country
Germany

Scientific contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Public contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 14 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
Boehringer Ingelheim Pharma GmbH & Co. KG
Global Clinical Development & Operations, Birkendorfer Strasse 65, 88397, Biberach An Der Riss

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2026-02-06 2026-04-10 2026-02-09 2026-02-11

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-10-27 Germany Acceptable
2025-12-01
2025-12-16
2 SUBSTANTIAL MODIFICATION SM-1 2026-01-12 Germany Acceptable
2026-01-29
2026-01-30